Risk of Benign Tumours of Nervous System, and of Malignant Neoplasms, in People with Neurofibromatosis: Population-based Record-linkage Study

Overview

Journal Br J Cancer

Specialty Oncology

Date 2012 Dec 22

PMID 23257896

Citations 89

Authors

O O Seminog

M J Goldacre

Affiliations

Soon will be listed here.

Abstract

Background: The neurofibromatoses (NF) are genetic disorders. Increased risks of some cancers in people with NF are well recognised, but there is no comprehensive enumeration of the risks across the whole range of site-specific cancers. Our aim was to provide this.

Methods: A linked data set of hospital admissions and deaths in England was used to compare rates of tumours in an NF cohort with rates in a comparison cohort, with results expressed as rate ratios (RR).

Results: The RR for all cancers combined, in people with both types of NF combined, was 4.3 (95% confidence interval (CI): 4.0-4.6), based on 769 cases of cancer in 8003 people with NF. Considering only people with presumed NF1 (as defined in the main article), the RR for all cancers excluding nervous system malignancies remained elevated (2.7, 95% CI: 2.4-2.9); and risks were significantly high for cancer of the oesophagus (3.3), stomach (2.8), colon (2.0), liver (3.8), lung (3.0), bone (19.6), thyroid (4.9), malignant melanoma (3.6), non-Hodgkin's lymphoma (3.3), chronic myeloid leukaemia (6.7), female breast (2.3) and ovary (3.7).

Conclusion: Neurofibromatosis was associated with an increased risk of many individual cancers. The relationships between NF and cancers may hold clues to mechanisms of carcinogenesis more generally.

Citing Articles

Pregnancy and the Risk for Cancer in Neurofibromatosis 1.

Kallionpaa R, Maattanen J, Leppavirta J, Peltonen S, Peltonen J Genes Chromosomes Cancer. 2025; 64(2):e70017.

PMID: 39985314 PMC: 11846020. DOI: 10.1002/gcc.70017.

Non-Optic Glioma-like Lesions in Adult Neurofibromatosis Type 1 Patients.

Taal W, Zick B, Emmer B, van den Bent M Diagnostics (Basel). 2025; 15(1.

PMID: 39795595 PMC: 11720024. DOI: 10.3390/diagnostics15010067.

Prediction of Cancer Proneness under Influence of X-rays with Four DNA Mutability and/or Three Cellular Proliferation Assays.

El Nachef L, Bodgi L, Estavoyer M, Bure S, Jallas A, Granzotto A Cancers (Basel). 2024; 16(18).

PMID: 39335159 PMC: 11430126. DOI: 10.3390/cancers16183188.

Neurofibromatosis type 1 adult surveillance form for Austria.

Sunder-Plassmann V, Azizi A, Farschtschi S, Gruber R, Hutterer M, Ladurner V Wien Klin Wochenschr. 2024; .

PMID: 39264447 DOI: 10.1007/s00508-024-02443-0.

Dissecting the Natural Patterns of Progression and Senescence in Pediatric Low-Grade Glioma: From Cellular Mechanisms to Clinical Implications.

Gorodezki D, Schuhmann M, Ebinger M, Schittenhelm J Cells. 2024; 13(14.

PMID: 39056798 PMC: 11274692. DOI: 10.3390/cells13141215.

References

Evans D, Howard E, Giblin C, Clancy T, Spencer H, Huson S . Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010; 152A(2):327-32. DOI: 10.1002/ajmg.a.33139. View

Ferner R, Hughes R, Hall S, Upadhyaya M, Johnson M . Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet. 2004; 41(11):837-41. PMC: 1735623. DOI: 10.1136/jmg.2004.021683. View

Breslow N, Day N . Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ. 1987; (82):1-406. View

Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I . A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer. 2006; 95(2):233-8. PMC: 2360616. DOI: 10.1038/sj.bjc.6603227. View

Evans D, OHara C, Wilding A, Ingham S, Howard E, Dawson J . Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet. 2011; 19(11):1187-91. PMC: 3198144. DOI: 10.1038/ejhg.2011.113. View

Viskochil D, Buchberg A, Xu G, Cawthon R, Stevens J, Wolff R . Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 1990; 62(1):187-92. DOI: 10.1016/0092-8674(90)90252-a. View

Rasmussen S, Yang Q, Friedman J . Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet. 2001; 68(5):1110-8. PMC: 1226092. DOI: 10.1086/320121. View

Goldacre M, Wotton C, Yeates D, Seagroatt V, Flint J . Cancer in people with depression or anxiety: record-linkage study. Soc Psychiatry Psychiatr Epidemiol. 2007; 42(9):683-9. DOI: 10.1007/s00127-007-0211-2. View

Goldacre M, Wotton C, Yeates D . Cancer and immune-mediated disease in people who have had meningococcal disease: record-linkage studies. Epidemiol Infect. 2008; 137(5):681-7. DOI: 10.1017/S0950268808001659. View

10.

Fois A, Wotton C, Yeates D, Turner M, Goldacre M . Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry. 2009; 81(2):215-21. DOI: 10.1136/jnnp.2009.175463. View

11.

Imaizumi Y . Mortality of neurofibromatosis in Japan, 1968-1992. J Dermatol. 1995; 22(3):191-5. DOI: 10.1111/j.1346-8138.1995.tb03369.x. View

12.

Zoller M, Rembeck B, Oden A, Samuelsson M, Angervall L . Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer. 1997; 79(11):2125-31. View

13.

Masocco M, Kodra Y, Vichi M, Conti S, Kanieff M, Pace M . Mortality associated with neurofibromatosis type 1: a study based on Italian death certificates (1995-2006). Orphanet J Rare Dis. 2011; 6:11. PMC: 3079598. DOI: 10.1186/1750-1172-6-11. View

14.

Johannessen C, Johnson B, Williams S, Chan A, Reczek E, Lynch R . TORC1 is essential for NF1-associated malignancies. Curr Biol. 2008; 18(1):56-62. DOI: 10.1016/j.cub.2007.11.066. View

15.

Stiller C, Chessells J, Fitchett M . Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer. 1994; 70(5):969-72. PMC: 2033537. DOI: 10.1038/bjc.1994.431. View

16.

Johannessen C, Reczek E, James M, Brems H, Legius E, Cichowski K . The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A. 2005; 102(24):8573-8. PMC: 1142482. DOI: 10.1073/pnas.0503224102. View

17.

Duong T, Sbidian E, Valeyrie-Allanore L, Vialette C, Ferkal S, Hadj-Rabia S . Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Orphanet J Rare Dis. 2011; 6:18. PMC: 3095535. DOI: 10.1186/1750-1172-6-18. View

18.

Sorensen S, Mulvihill J, Nielsen A . Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med. 1986; 314(16):1010-5. DOI: 10.1056/NEJM198604173141603. View

19.

Zoller M, Rembeck B, AKESSON H, Angervall L . Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Derm Venereol. 1995; 75(2):136-40. DOI: 10.2340/0001555575136140. View

20.

Burns E, Rigby E, Mamidanna R, Bottle A, Aylin P, Ziprin P . Systematic review of discharge coding accuracy. J Public Health (Oxf). 2011; 34(1):138-48. PMC: 3285117. DOI: 10.1093/pubmed/fdr054. View